JASMINE REYES: Open Payments
NPI 1669182051 · EL PASO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$683 in 37 payments from 10 companies in 2025. Trend: 2023 $527 · 2024 $597 · 2025 $683
Food & beverage: $683
| Company | Payments | Amount |
|---|---|---|
| Travere Therapeutics, Inc. | 10 | $109 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $97 |
| Ardelyx, Inc. | 4 | $95 |
| Otsuka America Pharmaceutical, Inc. | 4 | $87 |
| AstraZeneca Pharmaceuticals LP | 5 | $76 |
| Medtronic, Inc. | 1 | $64 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $56 |
| Aurinia Pharma U.S., Inc. | 2 | $39 |
| Apellis Pharmaceuticals, Inc. | 1 | $32 |
| SCPHARMACEUTICALS INC. | 2 | $29 |
Products named: IBSRELA, FARXIGA, JARDIANCE, ELLIPSYS VASCULAR ACCESS SYSTEM, Kerendia, JYNARQUE, VOYXACT, LUPKYNIS.
Industry payments across TX — which companies pay providers there.
